Abstracts tagged "risk assessment"

Abstract Number: 1486 • ACR Convergence 2022
Derivation and Internal Validation of a Disease-specific Cardiovascular Risk Prediction Model for Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Vinod Chandran³, Paula Harvey⁴, Richard Cook², Vincent Piguet⁴, Dafna Gladman⁵ and Lihi Eder⁶, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴Women's College Hospital, Toronto, ON, Canada, ⁵Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁶Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cardiovascular risk in patients with psoriatic disease (PsD) may be underestimated by conventional scoring systems. We derived and internally validated a 5-year disease-specific cardiovascular…
Abstract Number: L16 • ACR Convergence 2021
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled Electronic Medical Record Data Repository
Jasvinder Singh¹, Namrata Singh², Alfred Anzalone³, Amy Olex⁴, Jing Sun⁵, Vithal Madhira⁶ and Rena Patel⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Washington, Bellevue, WA, ³University of Nebraska, Omaha, NE, ⁴Virginia Commonwealth University, Richmond, VA, ⁵Johns Hopkins University, Baltimore, MD, ⁶Palila Software, Reno, NV, ⁷Unviersity of Washington, Seattle, WA
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether breakthrough COVID-19 infections were increased post-COVID-19-vaccination…
Abstract Number: 1135 • ACR Convergence 2021
Osteoporosis Assessment and Outcomes in Candidates for Liver Transplantation in a Tertiary Center
Cristina Rodríguez-Alvear¹, MARIANO ANDRES¹, Maria-Luisa Peral-Garrido², Irene Calabuig³, Ernesto Tovar-Sugrañes¹, Mari-Carmen López-González¹, Pilar Bernabeu¹, Agustín Martínez-Sanchis¹, Ximo Esteve¹, Paloma Vela¹, Cayetano Miralles¹ and Maria Vega Jovani Casano⁴, ¹Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain, ²Hospital General Universitario de Alicante-ISABIAL, Novelda, Spain, ³Hospital General Universitario de Alicante, Alicante, Spain, ⁴National Health system, Alicante, Spain
Background/Purpose: A rapid loss of bone mass and an increase in fractures have been described in the first six months after liver transplantation. This phenomenon…
Abstract Number: 1142 • ACR Convergence 2021
For Vulnerable Population Treated at a Community Health Center (CHC), Primary Care Physician (PCP) Turnover Should Be Included in Social Determinants of Health (SDH) on Non-completing Osteoporosis Treatment
Yu Na Kim¹ and Julie Crosson², ¹DotHouse Health, Boston, ²DotHouse Health, Boston University, Boston
Background/Purpose: Unexplained interruptions in treatment are common among patients with osteoporosis, but it is not well studied how PCP turnover affects incompletion of osteoporosis treatment…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 1527 • ACR Convergence 2021
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Michael Macklin¹, Chester Oddis², Siamak Moghadam-Kia², Dana Ascherman² and Rohit Aggarwal², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rituximab is an anti-CD20 antibody with therapeutic use in myositis. However, given its B cell depleting mechanism, there is concern regarding its association with…
Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 1612 • ACR Convergence 2021
Factors Associated with COVID-19 Vaccine Hesitancy Among Individuals with Rheumatic Disease
Kristin Wipfler¹, Adam Cornish¹, Alison Freifeld², Patricia Katz³ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of California San Francisco, San Francisco, CA
Background/Purpose: COVID-19 vaccination efforts are ongoing and there is a need to understand factors associated with vaccine hesitancy. Individuals with rheumatic diseases have been uniquely…
Abstract Number: 0091 • ACR Convergence 2021
Vaccination of Patients with Chronic Inflammatory Rheumatic Diseases: An Analysis of Barriers and Facilitators in a Prospective Cohort
Ioana Andreica, Iulia Roman, Xenofon Baraliakos, Juergen Braun and Uta Kiltz, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Patients (pts.) with chronic inflammatory rheumatic diseases (CIRD) are often not adequately protected against infectious diseases. As shown in an earlier study, less than…
Abstract Number: 1662 • ACR Convergence 2021
Unrecognised, Subclinical, Structural or Functional Lung Changes in Rheumatoid Arthritis Is Associated with a Higher Risk of Developing Serious Respiratory Tract Infection
Benjamin Worcester¹, Dorothy Wang², Susan Morton³ and Michelle Leech⁴, ¹Monash Health, Melbourne, Australia, ²Melbourne Health, Clayton, Australia, ³Monash Health, Clayton, Australia, ⁴Monash Medical Centre, Australia, Australia
Background/Purpose: The incidence of lung disease within the rheumatoid arthritis is well described and likely underestimated. Additionally, RA patients are at higher risk for developing…
Abstract Number: 0236 • ACR Convergence 2021
Maternal Attachment, Anxiety and Depressive Symptoms in Pregnant Women with Rheumatic Diseases
Luis Gerardo Espinosa-Banuelos¹, Diana Carolina Rubio Torres², Maria Corral², Cassandra Skinner Taylor², Lorena Perez-Barbosa², Luz Fernanda Gutierrez Leal², Abraham Yair Lujano-Negrete³, Jesus Cardenas-de La Garza² and Dionicio Galarza-Delgado², ¹Faculty of Medicine and University Hospital Dr. Jose Eleuterio Gonzalez, UANL, Monterrey, Mexico, ²Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, ³Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico
Background/Purpose: Untreated perinatal anxiety symptomatology can be related to symptoms of anxiety and depression during the postpartum. The psychological bond created by the mother between…
Abstract Number: 0285 • ACR Convergence 2021
Risk of Cardiovascular Disease in Newly Diagnosed Rheumatoid Arthritis: A Current Risk Assessment
Reinder Raadsen¹, Romy Hansildaar¹, Maaike Heslinga², Arno van Kuijk¹ and Michael Nurmohamed³, ¹Reade, Amsterdam, Netherlands, ²Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ³Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased risk of developing, mainly ischemic cardiovascular diseases (CVD). This is partly explained by…
Abstract Number: 0324 • ACR Convergence 2021
Machine Learning: Identifying Lupus Nephritis Within Systemic Lupus Erythematosus in the Real World
Bruno Teixeira, David Bell, Tim Holbrook and Ben Hoskin, Adelphi Real World, Bollington, United Kingdom
Background/Purpose: Around 40-70% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). LN is often underdiagnosed and early diagnosis is crucial for reducing…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0517 • ACR Convergence 2021
TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice
Alyson Dickson¹, Laura Daniel², Jacy Zanussi¹, Wei-Qi Wei¹, Dale Plummer¹, William Dupont³, Ge Liu¹, Prathima Anandi¹, Tyler Reese⁴, Kelly Birdwell¹, Vivian Kawai⁵, Adriana Hung¹, Qiping Feng¹, Nancy J. Cox¹, C. Michael Stein¹ and Cecilia Chung¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Pegram, TN, ³Vanderbilt University, Nashville, TN, ⁴Vanderbilt University Medical Center, Madison, TN, ⁵Vanderbilt Universty Medical Center, Nashville, TN
Background/Purpose: Azathioprine is frequently used for the treatment of several inflammatory conditions. However, treatment is often limited by adverse events, in particular myelotoxicity. Both thiopurine-S-methyltransferase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].